Showing results (51-60 of 71) with videos related to

Sort By:
Pageof 8
Cancer Immunology, Immunotherapy : CII|October 2, 2024
Efficacy and safety of lenvatinib combined with anti-PD-1 antibodies plus GEMOX chemotherapy as non-first-line systemic therapy in advanced gallbladder cancerYang Tan, Kai Liu, Chengpei Zhu, et al.
International Immunopharmacology|November 15, 2020
Comprehensive analysis of tumour mutation burden and the immune microenvironment in hepatocellular carcinomaFucun Xie, Yi Bai, Xu Yang, et al.
Advanced Materials (Deerfield Beach, Fla.)|September 12, 2021
Interfacial Laser-Induced Graphene Enabling High-Performance Liquid-Solid Triboelectric NanogeneratorYun Chen, Bin Xie, Junyu Long, et al.
International Journal of Surgery (London, England)|May 5, 2024
Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort studyShanshan Wang, Yunchao Wang, Chengpei Zhu, et al.
Nature Communications|August 7, 2021
Genomic characterization of co-existing neoplasia and carcinoma lesions reveals distinct evolutionary paths of gallbladder cancerJianzhen Lin, Xinxin Peng, Kun Dong, et al.
Hepatobiliary Surgery and Nutrition|August 23, 2024
Immunosuppression and phenotypic plasticity in an atlas of human hepatocholangiocarcinomaYiran Li, Ziyu Xun, Junyu Long, et al.
Hepatobiliary Surgery and Nutrition|August 25, 2021
Downstaging and resection of hepatocellular carcinoma in patients with extrahepatic metastases after stereotactic therapyXiaobo Yang, Haifeng Xu, Bangyou Zuo, et al.
Frontiers in Oncology|April 29, 2021
The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical StudyDongxu Wang, Xu Yang, Junyu Long, et al.
Annals of Translational Medicine|November 9, 2019
Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practiceJianzhen Lin, Kun Dong, Yi Bai, et al.
Cancer Immunology, Immunotherapy : CII|May 29, 2023
Efficacy, safety, and prognostic factors of PD-1 inhibitors combined with lenvatinib and Gemox chemotherapy as first-line treatment in advanced intrahepatic cholangiocarcinoma: a multicenter real-world studyChengpei Zhu, Hu Li, Xiaobo Yang, et al.
Pageof 8